Marketing of a new non-sedating antihistamine (fexofenadine) puts an additional burden on healthcare system resources in Israel.
Cohen
Arnon D
AD
Vardy
Daniel A
DA
Gan-El
Uni
U
Lieberman
Nicky
N
Reuvni
Haim
H
D003132:Commerce / Q000639:trends; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D003695:Delivery of Health Care / Q000191:economics*; D011307:Drug Prescriptions / Q000191:economics; D039563:Histamine H1 Antagonists, Non-Sedating / Q000191:economics*; D006801:Humans; D007557:Israel; D017336:Loratadine / Q000191:economics; D008389:Marketing of Health Services / Q000191:economics*; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000191:economics
D039563:Histamine H1 Antagonists, Non-Sedating; D017336:Loratadine; D016593:Terfenadine; C093230:fexofenadine